Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ravi I. Thadhani, M.D.

Co-Author

This page shows the publications co-authored by Ravi Thadhani and Eugene Rhee.
Connection Strength

1.740
  1. Rhee EP, Thadhani R. New insights into uremia-induced alterations in metabolic pathways. Curr Opin Nephrol Hypertens. 2011 Nov; 20(6):593-8.
    View in: PubMed
    Score: 0.540
  2. Simic P, Kim W, Zhou W, Pierce KA, Chang W, Sykes DB, Aziz NB, Elmariah S, Ngo D, Pajevic PD, Govea N, Kestenbaum BR, de Boer IH, Cheng Z, Christov M, Chun J, Leaf DE, Waikar SS, Tager AM, Gerszten RE, Thadhani RI, Clish CB, Jüppner H, Wein MN, Rhee EP. Glycerol-3-phosphate is an FGF23 regulator derived from the injured kidney. J Clin Invest. 2020 Mar 02; 130(3):1513-1526.
    View in: PubMed
    Score: 0.241
  3. Rhee EP, Guallar E, Hwang S, Kim N, Tonelli M, Moe SM, Himmelfarb J, Thadhani RI, Powe NR, Shafi T. Prevalence and Persistence of Uremic Symptoms in Incident Dialysis Patients. Kidney360. 2020 Feb; 1(2):86-92.
    View in: PubMed
    Score: 0.239
  4. Kalim S, Clish CB, Deferio JJ, Ortiz G, Moffet AS, Gerszten RE, Thadhani R, Rhee EP. Cross-sectional examination of metabolites and metabolic phenotypes in uremia. BMC Nephrol. 2015 Jul 07; 16:98.
    View in: PubMed
    Score: 0.174
  5. Kalim S, Clish CB, Wenger J, Elmariah S, Yeh RW, Deferio JJ, Pierce K, Deik A, Gerszten RE, Thadhani R, Rhee EP. A plasma long-chain acylcarnitine predicts cardiovascular mortality in incident dialysis patients. J Am Heart Assoc. 2013 Dec 05; 2(6):e000542.
    View in: PubMed
    Score: 0.156
  6. Rhee EP, Souza A, Farrell L, Pollak MR, Lewis GD, Steele DJ, Thadhani R, Clish CB, Greka A, Gerszten RE. Metabolite profiling identifies markers of uremia. J Am Soc Nephrol. 2010 Jun; 21(6):1041-1051.
    View in: PubMed
    Score: 0.121
  7. Titan SM, Venturini G, Padilha K, Goulart AC, Lotufo PA, Bensenor IJ, Krieger JE, Thadhani RI, Rhee EP, Pereira AC. Metabolomics biomarkers and the risk of overall mortality and ESRD in CKD: Results from the Progredir Cohort. PLoS One. 2019; 14(3):e0213764.
    View in: PubMed
    Score: 0.056
  8. Titan SM, Venturini G, Padilha K, Tavares G, Zatz R, Bensenor I, Lotufo PA, Rhee EP, Thadhani RI, Pereira AC. Metabolites related to eGFR: Evaluation of candidate molecules for GFR estimation using untargeted metabolomics. Clin Chim Acta. 2019 Feb; 489:242-248.
    View in: PubMed
    Score: 0.054
  9. Poyan Mehr A, Tran MT, Ralto KM, Leaf DE, Washco V, Messmer J, Lerner A, Kher A, Kim SH, Khoury CC, Herzig SJ, Trovato ME, Simon-Tillaux N, Lynch MR, Thadhani RI, Clish CB, Khabbaz KR, Rhee EP, Waikar SS, Berg AH, Parikh SM. De novo NAD+ biosynthetic impairment in acute kidney injury in humans. Nat Med. 2018 09; 24(9):1351-1359.
    View in: PubMed
    Score: 0.054
  10. Tavares G, Venturini G, Padilha K, Zatz R, Pereira AC, Thadhani RI, Rhee EP, Titan SMO. 1,5-Anhydroglucitol predicts CKD progression in macroalbuminuric diabetic kidney disease: results from non-targeted metabolomics. Metabolomics. 2018 02 27; 14(4):39.
    View in: PubMed
    Score: 0.052
  11. Kalim S, Wald R, Yan AT, Goldstein MB, Kiaii M, Xu D, Berg AH, Clish C, Thadhani R, Rhee EP, Perl J. Extended Duration Nocturnal Hemodialysis and Changes in Plasma Metabolite Profiles. Clin J Am Soc Nephrol. 2018 03 07; 13(3):436-444.
    View in: PubMed
    Score: 0.052
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.